As a new year begins, plans are underway for the 8 th Annual Rare Disease Genomics Symposium to be held on February 26 th and 27 th. The two-day event will be virtual this year to limit the spread of ...
CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mirdametinib is an investigational mitogen-activated ...
This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...
Findings from the ReNeu trial showed treatment with mirdametinib resulted in statistically significant objective response rates. The Food and Drug Administration (FDA) has accepted for Priority Review ...
Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements. The ...
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma The following represents disclosure information ...
Cred: SpringWorks Therapeutics. Mirdametinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2. Gomekli is the first medication approved for both adult and pediatric patients with ...
At its May 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for mirdametinib (Ezmekly, Springworks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback